Regeneron Targets Stroke Prevention Gap With New Atrial Fibrillation Trial
Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study.
Memorial Day Sale – Claim 70% Off TipRanks
- Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
- Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
Regeneron Pharmaceuticals is running a late-stage study called ROXI-INCLINE to test new ways to prevent stroke and blood clots in people with atrial fibrillation who cannot use common blood thinners. The trial aims to show whether two antibodies, REGN7508 and REGN9933, can safely cut the risk of stroke and other serious events in this high-need group.
The study is testing two injected drugs, REGN7508 and REGN9933, which target factor XI, a protein that helps blood clot. The goal is to block harmful clots linked to atrial fibrillation while trying to avoid the bleeding risks often seen with standard blood thinners.
This is a Phase 3, randomized trial that assigns participants by chance to REGN7508, REGN9933, or placebo. It is double-blind, so patients, doctors, and trial staff do not know who gets which treatment, and the main goal is to prevent strokes and systemic embolism rather than to treat symptoms.
The trial was first submitted on 18 February 2026, showing that enrollment is still in the early to mid phase. The record was last updated on 26 May 2026, which signals that the protocol or operational plans have been refined as the study ramps up.
For investors, this program positions Regeneron in the fast-growing market for safer clot-prevention drugs, where large players like Bristol Myers Squibb and Pfizer already sell oral therapies. Positive data could support a new franchise in cardiovascular care and lift sentiment on REGN, while setbacks may temper expectations for non-eye pipeline growth.
The ROXI-INCLINE study remains active and recruiting, and further details and updates are available on the ClinicalTrials.gov portal.
To learn more about REGN’s potential, visit the Regeneron Pharmaceuticals drug pipeline page.
